Lect Final 86% Flashcards
Infant Sample collection
- Must minimize the amount of sample drawn, due to small blood volume in infants
“Well” infants experience
– Immune thrombocytopenia, vitamin K deficiency,
hemophilia, bleeding from a localized vascular lesion
sick infants
– Prematurity, perinatal infection, respiratory distress
syndrome, metabolic derangements, birth asphyxia
▪ DIC, liver failure, isolated platelet consumption defect
Identifying aPL Antibodies
- Prolongation of a PL-dependent coagulation test (e.g.,
APTT, dRVVT, KCT) - Evidence of inhibitor activity (lack of correction by a 1:1
mix with normal plasma) - Confirmation that inhibitory effect blocks PL-dependent
coagulation (i.e., neutralization of inhibitor effect by
addition of excess PLs or changing PL source) - Absence of specific inhibitor against a coagulation factor
Antiphospholipid Antibody Syndrome
(APLS
-Not clearly understood
-presents as VTE (DVT, PE), arterial thromboses (stroke, TIA, MI)
- recurrent miscarriages
- Antiphospholipid antibodies
▪ Lupus anticoagulant (LA)
▪ Anticardiolipin antibodies (aCL)
▪ Several subgroups—antibodies to PLs and PL binding
proteins
negatively charged surface
repels platelet and hemostatic proteins
heparan sulfate(HS)
inhibits fibrin formation - cofactor for antithrombin
thrombomodulin(TM)
binds thrombin and enhances activation of protein C
endothelial protein C receptor
binds protein C and facilitates PC activation
Tissue Factor pathway inhibitor TFPI
Binds TF/FVIIA/FXa complex
inhibits extrinsic pathway of coagulation
Postacyclin PGI2
promotes vasodilation, inhibits platelet activation
Tissue plasminogen activator tPA
activates fibrinolysis system
Annexin A2 -tPa receptor A2
binds tPA and plasminogen, activates finbrinolysis
Urinary type plasminogen activator
binds uPAR and plasminogen, activates fifrinolysis